Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.
Oqory's anti-TROP2 ADC, OQY-3258, demonstrates promising Phase 1a/1b results in solid tumors, particularly in breast cancer subtypes, showcasing high overall response rates.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.